Cardio Diagnostics Holdings, Inc. Teams Up with YMCA of East Tennessee to Provide Heart Health Education and Advanced Testing for the Local Community

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Oct 28 2025

0mins

CDIO+22.86%

Should l Buy CDIO?

Source: Newsfilter

Partnership Announcement: Cardio Diagnostics is partnering with the YMCA of East Tennessee to offer a customized program for its members, which includes educational sessions called "Wisdom Wednesdays" and discounted access to AI-powered cardiovascular tests.
Heart Disease Statistics: Heart disease is the leading cause of death in the U.S., with Tennessee having a notably high cardiovascular mortality rate, highlighting the importance of early detection and prevention initiatives.
Educational Initiatives: The program will feature six educational sessions starting in November 2025, focusing on coronary heart disease prevention and proactive heart health management.
Community Access: The collaboration aims to extend cardiovascular testing and educational resources beyond YMCA members to the entire East Tennessee community, promoting heart health awareness and proactive measures.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CDIO?" and start using high-conviction signals backed by rigorous historical data.

CDIO

$1.29+Infinity%1D

Analyst Views on CDIO

About CDIO

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test

Jan 08 2026Benzinga

International Expansion: Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs Ltd. to introduce the PrecisionCHD coronary test in India, marking the company's first expansion outside the U.S. and targeting a market with rising heart disease rates.
Technological Innovation: The PrecisionCHD test combines epigenetics, genetics, and AI to detect coronary heart disease at a molecular level from blood samples, addressing the urgent screening demand in urban areas of India where heart disease rates can reach as high as 13%, filling a gap left by traditional angiograms.
Clinical Integration Progress: The partners have begun integrating the test into Dr. Lal PathLabs' clinical and lab network, with broader commercial deployment expected in 2026 under Indian clinical guidelines, enhancing access to advanced heart diagnostics.
Executive Insights: Cardio Diagnostics CEO Dr. Meesha Dogan stated that the partnership advances equitable access to cutting-edge cardiovascular care, while Aimil's Executive Director Dr. Mallika Kapoor emphasized that this venture strengthens India's access to advanced heart diagnostics.

Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs

Jan 07 2026NASDAQ.COM

Market Expansion: Cardio Diagnostics Holdings partners with Aimil Ltd. and Dr. Lal PathLabs Ltd. to launch the PrecisionCHD test, marking the company's first expansion outside the U.S. and official entry into the Indian market, which is crucial given the rising prevalence of cardiovascular diseases.
Technological Innovation: The PrecisionCHD test can identify non-obstructive coronary heart disease, surpassing traditional angiography, thereby enabling doctors to provide personalized treatment plans that enhance the quality and effectiveness of healthcare services.
Commercial Outlook: The test is expected to be commercially launched in 2026, with initial promotion through Dr. Lal PathLabs' laboratory and clinical network, a strategy that will facilitate rapid adaptation to Indian clinical and regulatory protocols, thereby increasing market acceptance.
Market Reaction: Following the announcement, CDIO's stock surged 29.61% in pre-market trading, indicating a positive market response to this strategic partnership and reflecting investor confidence in the company's future growth potential.

Cardio Diagnostics Partners with Southdale YMCA to Enhance Heart Health Education for 14,000 Members

Jan 06 2026Businesswire

Heart Health Collaboration: Cardio Diagnostics partners with Southdale YMCA to provide heart health education and advanced cardiovascular testing to over 14,000 members, enabling the community to better manage cardiovascular risk.
Educational Event Scheduled: An in-person heart health education event is set for January 26, 2026, led by Chief Medical Officer Dr. Robert Philibert, offering practical guidance to reduce heart disease risk and enhance community health awareness.
Heart Health Fair: The Southdale YMCA will host a Heart Health Fair on February 25, 2026, providing access to heart health resources and Cardio Diagnostics' clinical tests, promoting community engagement in heart health.
Access to Advanced Testing: Members will benefit from discounted rates on Epi+Gen CHD™ and PrecisionCHD™, two clinically validated tests that assess heart disease risk through simple blood draws, facilitating broader heart disease prevention and management efforts.

Cardio Diagnostics Holdings, Inc. to Showcase Data Highlighting PrecisionCHD's Capability to Identify INOCA and MINOCA at the American Heart Association Scientific Sessions

Nov 05 2025Newsfilter

Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.
PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.
Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.
Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.